Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:00 2025-07-07 am EDT			5-day change	1st Jan Change
97.61 ^CHF	-0.52%		+1.49%	+10.05%

Jul. 07	Sector Update: Tech	MT
Jul. 07	Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	MT

Brussels seeks companies' US spending plans as Trump hails move toward talks

Published on 05/27/2025 at 15:11

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

Sector Update: Tech	Jul. 07	MT
Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	Jul. 07	MT
GSK Finalizes Acquisition of Boston Pharmaceuticals' Liver Disease Drug Candidate	Jul. 07	MT
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Swiss Market Index Closes Flat; Drugmakers Gain on US-Swiss Trade Deal Talks	Jul. 04	MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Jul. 04	ZD
European Equities Close Mostly Higher in Thursday Trading; EU Targets July 9 for US Trade Deal	Jul. 03	MT
Switzerland seeks trade deal with Trump without getting into EU bind	Jul. 03	RE
Swiss Market Index Closes Lower; Novartis Shares Down	Jul. 03	MT
NOVARTIS AG : UBS remains Neutral	Jul. 03	ZD
Novartis Drug Cosentyx Falls Short in Late-stage Trial for Giant Cell Arteritis	Jul. 03	MT
Novartis Says Cosentyx Fails to Meet Primary Endpoint in Phase 3 Giant Cell Arteritis Study	Jul. 03	MT
Novartis: Consentyx fails in Phase III	Jul. 03	CF
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx in Giant Cell Arthritis	Jul. 03	CI
Novartis' Cosentyx Misses Primary Endpoint in Late-stage Giant Cell Arteritis Study	Jul. 03	MT
Novartis's Cosentyx Fails to Meet Primary Goal at Late-Stage Trial	Jul. 03	DJ
Novartis drug Cosentyx fails late-stage trial for artery disease	Jul. 03	RE
Novartis provides update on Phase III GCAptAIN study of Cosentyx(R) in giant cell arteritis (GCA)	Jul. 03	DJ
NOVARTIS AG : Goldman Sachs reaffirms its Neutral rating	Jul. 02	ZD
NOVARTIS AG : UBS is Neutral	Jul. 01	ZD
US FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6	Jun. 30	RE
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	Jun. 30	RE
Novartis, Profound Therapeutics Enters Cardiovascular Medicine Development Partnership	Jun. 26	MT
Fitch Keeps Novartis' Rating on Leading Position in Pharma Industry	Jun. 26	MT
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..	Jun. 25	CI

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company